Ubiquitin Proteosome Drugs: Cancer and Neurodegenerative Disorder Markets

Ubiquitin Proteosome Drugs: Cancer and Neurodegenerative Disorder Markets published by BCC Research in July, 2010. This report consists of 145 Pages and the price starts from US $ 4850.

Introduction

Abstract

HIGHLIGHTS:

• There is only one approved UPS product on the market, Velcade, a proteasome inhibitor, with total sales of more than $1.4 billion in 2009. This drug is expected to be worth $3 billion in 2015, a compound annual growth rate (CAGR) of 13.5% over the study period.
• In the U.S., Velcade was worth $468 million in 2009 and is expected to reach $1 billion in 2015, a compound annual growth rate (CAGR) of 13.5%.
• Worldwide, Velcade was valued at $933 million in 2009 and is expected to reach $2 billion by 2015, a compound annual growth rate (CAGR) of 13.6%.

SCOPE AND ANALYST

This BCC Research report, Ubiquitin Proteasome Drug Discovery: Cancer and Neurodegenerative Markets, provides an overview of the current state of drug discovery in the ubiquitin proteasome research field, existing products on the market, and detailed analysis of the competitive environments, including new potential markets for current research projects. The study includes information about significant players in this field of study, trends, and challenges, and other information affecting drug discovery in the ubiquitin proteasome system (UPS).

The scientists who discovered the UPS were awarded the Nobel Prize in Chemistry in 2004. UPS represents one of the most-studied and challenging areas in basic and applicable science. Since 2004, ubiquitin ligases and proteasome function have become one of the major targets for pharmaceutical and drug development companies. Yet, despite the accumulation of basic knowledge about the mechanism of action of this cellular phenomenon, progress in drug screening and therapeutic development has been delayed. However, the proven success of the proteasome inhibitor bortezomib in addition to a recent breakthrough in the identification of new drug candidates in the UPS research field bring new excitement and hope for further successful drug development. More importantly, the real commercial potential of this research area has not yet been fully acknowledged. This study will provide knowledge of the current state of drug discovery in this field and new technologies in assay development, and, more importantly, will describe potential novel commercial venues in this drug discovery.

This subject is relatively new to the market research report format and provides business tools to evaluate new commercial opportunities in the drug discovery field. The geographic scope of this study covers U.S. and global companies. The report identifies two major research trends in UPS: proteasome inhibitors versus ubiquitination reaction components as drug targets. This study describes current products in each area, identifies current market participants and, most importantly, notes the trends that are going to affect further drug development in this area. The report also provides information about less-developed areas of UPS, and gives a list of current companies that have new UPS-related products in development.

The research methodology used in this report has been qualitative in nature and has employed a triangulating approach, which aids in validity. Initially, a comprehensive and exhaustive search of the literature on drug discovery and already-marketed products was conducted. These secondary sources included drug discovery and science-related journals, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports, and other publications. A patent search and analysis were also conducted. In a second phase, a series of semistructured interviews were conducted with company representatives, bench scientists, marketing representatives, and other personnel at biotech and pharmaceutical companies. Other resources included academics, technology, and consulting companies. These were rich sources of data. Subsequent analysis of the documents and interview notes was iterative.

This report is intended for business development professionals, entrepreneurs, and other investment groups so that they can fully understand and evaluate a new, less-familiar area of drug discovery and development. It provides companies' corporate development departments new insight into competitors' positions and shows new opportunities otherwise overlooked or less known to the public.

Dr. Marianna Tcherpakov has more than 7 years' experience as a bench scientist specializing in the area of UPS research. She has contributed to a number of scientific publications and holds several patents. She has expertise as an assay development scientist and is familiar with this research field's trends and likely future developments.

Table of Contents

Ubiquitin Proteosome Drugs: Cancer and Neurodegenerative Disorder Markets

Chapter- 1: INTRODUCTION -- Complimentary

• STUDY GOALS AND OBJECTIVES
• REASONS FOR DOING THIS STUDY
• SCOPE OF REPORT
• METHODOLOGY AND INFORMATION SOURCES
• INTENDED AUDIENCE
• ANALYST CREDENTIALS
• RELATED REPORTS
• BCC ONLINE SERVICES
• DISCLAIMER

Chapter-2: SUMMARY

• SUMMARY
• SUMMARY TABLE A U.S. AND WORLDWIDE NET SALES OF VELCADE, THROUGH 2015 ($ MILLIONS)
• SUMMARY FIGURE U.S. AND WORLDWIDE NET SALES OF VELCADE, 2007-2015 ($ MILLIONS)
• SUMMARY TABLE B GLOBAL MARKET SHARES OF MILLENNIUM/TAKEDA, CELGENE, AND OTHER DRUG COMPANIES, 2009 (%)

Chapter-3: OVERVIEW OF SCIENTIFIC BACKGROUND, AND SIGNIFICANCE OF UPS RESEARCH

• UBIQUITINATION PHENOMENA AND ITS MAJOR COMPONENTS
• ENZYMATIC COMPONENTS AS POSSIBLE DRUG TARGETS
  • TABLE 1 ENZYMATIC COMPONENTS OF UBIQTUINATION/ DEUBIQUITINATION REACTION
  • FIGURE 1 ENZYMATIC STEPS IN UBIQUITINATION REACTION
  • FIGURE 2 HIERARCHICAL STRUCTURE OF UPS
• CHAIN TOPOLOGY AS A SIGNALING PATHWAY
• PROTEASOME MACHINERY
• STRUCTURE AND FUNCTION
• PROTEASOME AS A TARGET FOR DRUG DISCOVERY
• UBIQUITIN-LIKE MODIFIERS (UBLS)
  • TABLE 2 UBLS, THEIR FUNCTION AND ASSOCIATED PATHOLOGY WITH THEIR DYSFUNCTION
• UBIQUITIN-LIKE MODIFIERS (UBLS) (CONTINUED)

Chapter-4: MAJOR DRUG DEVELOPMENT AND PRODUCTS IN THE UPS RESEARCH FIELD

• INDUSTRY OVERVIEW
• PROTEASOME AS A DRUG DISCOVERY
• Velcade: The First UPS Product
• Chemical Structure of Velcade and Its Mechanism of Action
  • FIGURE 3 CHEMICAL STRUCTURE OF BORTEZOMIB
• Pharmacodynamics, Administration, and Side Effects
• Velcade Sales Market
• Overview
  • TABLE 3 U.S. STATISTICS FOR HEMATOLOGICAL MALIGNANCIES, 2009 (NUMBER)
• MM Symptoms and Treatment
• General Treatment for MM Today
  • TABLE 4 PROJECTED SIZE OF THE WORLDWIDE MM DRUG MARKET, 2009 AND 2018 ($ BILLIONS)
• NHL and Mantle Cell Lymphoma
• Treatments for Mantle Cell Lymphoma and Other NHL
• CHOP Therapy
• MabThera/Rituxan
• Current Major Market Participants in MM Treatment and Sales Forecast
• Millennium Pharmaceuticals (a Subsidiary of Takeda)
  • TABLE 5 U.S. AND WORLDWIDE NET SALES OF VELCADE, THROUGH 2015 ($ MILLIONS)
  • FIGURE 4 U.S. AND WORLDWIDE NET SALES OF VELCADE, 2007-2015 ($ MILLIONS)
• Celgene
• Revlimid
• Thalomid
  • TABLE 6 WORLDWIDE NET SALES OF REVLIMID AND THALOMID, THROUGH 2016 ($ MILLIONS)
  • FIGURE 5 WORLDWIDE NET SALES OF REVLIMID AND THALOMID, 2006-2016 ($ MILLIONS)
• Market Shares of Millennium/Takeda, Celgene, and Other Companies' Drugs
  • TABLE 7 WORLDWIDE SHARES OF THE MM TREATMENT MARKET: MILLENNIUM/TAKEDA, CELGENE, AND OTHER DRUG COMPANY SHARES IN 2009 COMPARED TO THOSE PROJECTED IN 2011* (%)
  • FIGURE 6 WORLDWIDE SHARES OF THE MM TREATMENT MARKET: MILLENNIUM/TAKEDA, CELGENE, AND OTHER DRUG COMPANY SHARES IN 2009 COMPARED TO PROJECTED SHARES IN 2011* (%)
  • FIGURE 6 (CONTINUED)
• Millennium Pharmaceuticals/Takeda's New Developments
  • TABLE 8 EXAMPLE OF COSTS OF SIDE EFFECTS OF CHEMOTHERAPY TREATMENT PER PATIENT IN THE U.S., 2006 ($ THOUSANDS)
• New Formulations for Velcade and Second-Generation Inhibitors
• Improvement of Velcade
• Second-Generation Inhibitor MLN9708
  • TABLE 9 CURRENT R&D ACTIVITY IN UPS BY MILLENNIUM/TAKEDA
• Velcade in Combination with Other Treatments
• COMPANIES WORKING ON SECOND-GENERATION PROTEASOME INHIBITORS
• OVERVIEW
• Current Market Participants
  • TABLE 10 COMPANIES WITH CURRENT R&D IN PROTEASOME INHIBITION AS A DRUG TARGET
• Millennium Pharmaceuticals (a Subsidiary of Takeda)
• Onyx Pharmaceuticals/Proteolix
• Carfilzomib
• ONX 0912
• ONX 0914 (PR-957)
  • TABLE 11 WORLDWIDE MARKET FOR AUTOIMMUNE DISORDERS: LUPUS, RA, AND IBD, 2008 ($ BILLIONS)
• Cephalon
• CEP-18770
• Nereus Pharmaceuticals
• Salinosporamide (NPI-0052)
• ADDITIONAL MARKETS FOR PROTEASOME ACTIVATORS/INHIBITORS
• OVERVIEW
• Proteasome Inhibition as Tuberculosis (TB) Treatment
• Worldwide and U.S. Statistics for TB
  • TABLE 12 STATISTICS FOR TB INFECTION WORLDWIDE AND IN THE U.S., 2009 (MILLIONS)
• Drug Treatments for TB
  • TABLE 13 WORLDWIDE MARKET FOR TB DRUG TREATMENTS, 2000 AND 2009 ($ MILLIONS)
  • FIGURE 7 WORLDWIDE MARKET FOR TB DRUG TREATMENTS, 2000 AND 2009 ($ MILLIONS)
• New Approach for TB Drug Development
• Proteasome Inhibition as Dry Eye Treatment
• Overview
• Treatments for Dry Eye and Market Worth
  • TABLE 14 WORLDWIDE MARKET FOR DRY EYE TREATMENTS, 2009 AND 2014 ($ BILLIONS)
• Alcon, Inc. as a Manufacturer of Proteasome Inhibitor for Dry Eye Treatment
• Proteasome Activity Alteration in Dermatology and Skin Care Industry
• Proteasome Inhibitor as Hair Loss Treatment
  • TABLE 15 U.S. MARKET FOR HAIR LOSS TREATMENTS, 2009 ($ BILLION)
• Proteasome Activity Modulators as Skin Care and Cosmetic Treatment
  • TABLE 16 U.S. SKIN CARE AND COSMETIC MARKET, 2009 ($ BILLIONS)
• UBIQUITINATION ENZYMES AS A TARGET FOR DRUG DISCOVERY
• E1 LIGASE AS A TARGET FOR DRUG DISCOVERY
• Overview
  • TABLE 17 CURRENT DRUG DISCOVERIES FOR E1 INHIBITORS
• PYR-41, THE FIRST E1 INHIBITOR
• NAE-E1 FOR NEDDYLATION AS A DRUG TARGET
• Overview
• MLN4924- NAE-1 Inhibitor by Millennium Pharmaceuticals (a Subsidiary of Takeda)
• Benzothiazole/Thiazole Pyridine
• E2 LIGASE AS A TARGET FOR DRUG DISCOVERY
• Overview
• Possible Commercial Opportunities and Markets for E2 Ligases
  • TABLE 18 E2S AS A DRUG DISCOVERY TARGET AND ITS MARKET POTENTIAL ($ BILLIONS)
• Blood Disorders Market for E2s
• Ube2T: Fanconi Anemia
• Spectrin Sickle-Cell Disease (SCD)
  • TABLE 19 WORLDWIDE MARKET FOR SCA TREATMENTS, 2009 (NUMBER OF PATIENTS)
• Oncology and the Immune Disorders Market for E2s
• Role of UbcH10 in Cancer
• Ubc13 Cancer/Immune Disorders
• Neurodegenerative Disorders Market for E2s
• E2-25K Alzheimer's and Huntington's Diseases
• E3 LIGASES AS A DRUG DISCOVERY TARGET
• Overview
  • TABLE 20 COMPANIES WORKING ON E3 LIGASES AS DRUG TARGETS
• HDM2 AS A TARGET FOR DRUG DISCOVERY
• P53 as a Drug Target in General
• Overview
• P53-Activating Compounds
• Gene Therapy
  • TABLE 21 COMPANIES WITH R&D IN P53 GENE THERAPY
• Companies Developing p53
• Introgen
• Schering-Plough (Merck)
• Onyx Pharmaceuticals
• Head and Neck Cancer as a Market Target for p53 Therapy
• Ovarian Cancer as a Market Target for p53 Therapy
  • TABLE 22 U.S. STATISTICS AND WORLDWIDE MARKET FOR HEAD AND NECK AND OVARIAN CANCERS, 2009 (NUMBER/$MILLIONS)
• Hdm2-p53 Strategy for Drug Discovery
• Overview
• Current Drug Development Participants
  • TABLE 23 COMPANIES AND DRUG CANDIDATES IN HDM2-P53 DRUG DISCOVERY
• Hoffmann-La Roche
• Amgen
• Johnson & Johnson (Ortho Biotech Oncology Research and Development)
• Aprea AB
• Ascenta Therapeutics
• Rigel Pharmaceuticals
• Priaxon AG
• Novelix Pharmaceuticals
• Meso Scale Discovery
• GSK
• Cytomics Pharmaceuticals
• THE IAP FAMILY AS A TARGET FOR DRUG DISCOVERY
• Overview
• Strategy to Target IAP Function
• siRNA
• Inhibition of Ubiquitin Ligase Activity
• Disruption of IAP and Caspase Interaction
• Companies Currently Working on IAPs as a Drug Target
  • TABLE 24 CURRENT COMPANIES WITH IAP DRUGS IN CLINICAL TRIALS
• Genentech
• Novartis
• Ascenta Therapeutics
• Aegera Therapeutics
• AEG35156
• AEG40826
• AEGXXXX
• TetraLogic Pharmaceuticals
• Astellas Pharma
• Market Potential for IAP Drug Discovery
  • TABLE 25 POTENTIAL WORLDWIDE MARKET FOR IAP DRUG DISCOVERY, 2009 ($ BILLIONS)
• ADDITIONAL E3 UBIQUITIN LIGASES AS TARGETS FOR DRUG DISCOVERY
• OVERVIEW
  • TABLE 26 E3 UBIQUITIN LIGASES IN DRUG DISCOVERY, 2005 TO 2010
• APC Ligase Complex
• SCF Complex
• TRAF6
• MuRF1
• Praja1
  • TABLE 27 U.S. AND PROJECTED WORLDWIDE OSTEOPOROSIS MARKET, 2009 (NUMBER/$ BILLIONS)
• Hrd1
  • TABLE 28 U.S. AND PROJECTED WORLDWIDE RA MARKET, 2009 AND 2030 (NUMBER/$ BILLIONS)
• Parkin
• Posh1
• GENERAL MARKET POTENTIAL FOR E3 UBIQUITIN LIGASES IN DRUG DISCOVERY
  • TABLE 29 PROJECTED WORLDWIDE MARKETS FOR CURRENT PROJECTS IN E3 LIGASE DRUG DISCOVERY BY DISEASE TYPE, 2009 ($ BILLIONS)
• POSSIBLE ADDITIONAL E3 LIGASES AS A DRUG TARGET
• Overview
  • TABLE 30 ADDITIONAL E3 LIGASES AS POTENTIAL DRUG DISCOVERY TARGETS ($ BILLIONS)
• AO7
• SMURF1
• TRIM25
• BRCA1
• LUBAC
• Breast Cancer as a Potential Therapeutic Market
• Breast Cancer Statistics
  • TABLE 31 U.S. BREAST CANCER IN WOMEN, 2009 (NUMBER)
• Breast Cancer Treatments and Market Size
  • TABLE 32 WORLDWIDE MARKET FOR BREAST CANCER THERAPEUTICS, 2007 AND 2013 ($ BILLIONS)
  • FIGURE 8 WORLDWIDE MARKET FOR BREAST CANCER THERAPEUTICS, 2007 AND 2013 ($ BILLIONS)
• COMPANIES WITH A WIDE GENERAL PLATFORM FOR DRUG DISCOVERY IN UPS
• OVERVIEW OF CURRENT COMPANIES WITH GENERAL RESEARCH PLATFORM IN UPS
• CellXplore
• COMPANIES AND THE BREAST CANCER DIAGNOSTICS MARKET
• Current Blood Test Markers
• Current Participants in the Development of Blood Tests for Breast Cancer Diagnostics
• Chronix Biomedical
• Diagenic ASA
• Martell Biosystems
• Market Potential for Breast Cancer Blood Test Diagnostics
  • TABLE 33 U.S. AND WORLDWIDE MARKETS FOR BREAST CANCER DIAGNOSTICS, 2006 AND 2009 ($ MILLIONS)
• Proteologics
• Cytomics Pharmaceuticals
• Candidiasis and Potential Market Opportunity
  • TABLE 34 U.S. AND WORLDWIDE MARKET FOR ANTIFUNGAL TREATMENTS, 2007 ($ BILLIONS)
• Ubiquigent
• INVESTMENT AND ACQUISITIONS IN UPS COMPANIES
• OVERVIEW
  • TABLE 35 WORLDWIDE INVESTMENT AND ACQUISITIONS IN UPS COMPANIES, 2007-2010 ($ MILLIONS)
• Proteologics
• Priaxon AG
• Proteolix (Onyx)
• CellXplore
• Neosil, Inc.
• Ubiquigent
• COLLABORATIONS
• OVERVIEW
  • TABLE 36 RECENT COLLABORATIONS BETWEEN ACADEMIA AND INDUSTRY
• LifeSensors
• Progenra
• GNI
• Stemgent
• Ascenta Therapeutics
• Proteologics
• Millennium Pharmaceuticals
• Senetek PLC
• UPS AS A POTENTIAL DIAGNOSTIC TOOL
• OVERVIEW
• Neurodegenerative Disorders
  • TABLE 37 STATISTICS AND COST OF ALZHEIMER's AND PARKINSON's IN THE U.S., 2008 (NUMBER/$ BILLIONS)
• UPS as a Potential Diagnostic Tool in Neurodegeneration
• IBD (Inflammatory Bowel Syndrome)
  • TABLE 38 STATISTICS AND COST OF IBD IN THE U.S., 2008 (NUMBER/$ BILLIONS)
• UPS as a Potential Diagnostic Tool in IBD
• Biomarkers for HCC in Cirrhosis Patients
  • TABLE 39 STATISTICS AND COST OF HCC IN THE U.S., 2009 (NUMBER/$ MILLIONS)
• UPS as a Potential Diagnostic Tool in HCC
• Current Development of UPS as Diagnostic Tool

Chapter-5: INTRODUCTION

• OVERVIEW
• DUBS AND THEIR ROLE IN PATHOLOGY
  • TABLE 40 DUBS AND THEIR ROLE IN CLINICAL CONDITIONS
• POTENTIAL MARKETS BY DISEASE TYPE
• CANCER
• NEURODEGENERATION
• HEMOTOLOGICAL DISORDERS
  • TABLE 41 WORLDWIDE MARKETS FOR DUB DRUG DISCOVERY BY CLINICAL CONDITION, 2009 ($ BILLIONS)
• COMPANIES THAT WORK ON DUB AS A DRUG TARGET
  • TABLE 42 COMPANIES WORKING ON DUB AS A DRUG TARGET
• PROGENRA
• USP7 as a Drug Target
• USP20 and USP33 as Drug Targets
  • TABLE 43 STATISTICS AND COST OF MEDICAL CARE FOR KIDNEY CANCER IN THE U.S., 2009 (NUMBER/$ BILLIONS)
• HYBRIGENICS
• GENENTECH
• NOVARTIS
  • TABLE 44 STATISTICS AND COST OF MEDICAL CARE FOR LUNG AND COLON CANCER IN THE U.S., 2009 (NUMBER/$ BILLIONS)
• Competitive Analysis

Chapter-6: UBIQUITIN-LIKE MODIFIERS AS TARGETS FOR DRUG DISCOVERY

• OVERVIEW
• SUMOYLATION MODIFICATION AS A DRUG TARGET STRATEGY
• Enzymatic Machinery of Sumoylation as a Drug Target
  • TABLE 45 ENZYMATIC MACHINERY OF SUMOYLATION
• Commercial Potential of Sumoylation Drug Discovery
  • TABLE 46 PROJECTED WORLDWIDE MARKETS FOR SUMOYLATION DRUG DISCOVERY BY PATHOLOGY, 2009 (NUMBER/$ BILLIONS)
• Current Participants in Sumoylation Drug Discovery
• ISG15 MODIFICATION AS A DRUG TARGET STRATEGY
• NEDDYLATION MODIFICATION AS A DRUG TARGET STRATEGY
• POTENTIAL MARKET FOR UPS DRUG DISCOVERY IN NEURODEGENERATIVE DISORDERS
• OVERVIEW
  • TABLE 47 U.S. MARKET FOR REPRESENTATIVE NEURODEGENERATIVE DISORDERS AND THEIR INCIDENCE, 2009 ($ BILLIONS/NUMBER)
• PARKINSON's DISEASE AND ITS CURRENT DRUG TREATMENT
  • TABLE 48 WORLDWIDE NET SALES OF MIRAPEX AND REQUIP, 2007 - 2009 ($ MILLIONS)
• ALZHEIMER's AND ITS CURRENT DRUG TREATMENT
  • TABLE 49 WORLDWIDE NET SALES OF NAMENDA AND ARICEPT, 2007 - 2009 ($ MILLIONS)
• HUNTINGTON's DISEASE AND ITS CURRENT DRUG TREATMENTS
  • TABLE 50 WORLDWIDE MARKET FOR HUNTINGTON's DISEASE TREATMENTS, AND INCIDENCE OF HUNTINGTON's IN THE U.S., 2009 ($ MILLIONS/NUMBER)
• CURRENT UPS COMPANIES THAT TARGET THE NEURODEGENERATIVE DISORDERS MARKET IN DRUG DISCOVERY
• POTENTIAL MARKET FOR UPS DRUG DISCOVERY IN IMMUNE DISORDERS
• OVERVIEW
  • TABLE 51 WORLDWIDE STATISTICS AND MARKET FOR MS AND RA, 2009 ($ BILLIONS/NUMBER)
• MS AND ITS CURRENT DRUG TREATMENTS
  • TABLE 52 WORLDWIDE NET SALES OF COPAXONE AND TYSABRI, 2007 - 2009 ($ MILLIONS)
• UPS as a Drug Treatment in MS
• RA AND ITS CURRENT DRUG TREATMENTS
  • TABLE 53 AMGEN's WORLDWIDE NET SALES OF KINERET AND ENBREL, 2008 ($ MILLIONS)
• CURRENT UPS COMPANIES THAT TARGET THE IMMUNE DISORDERS MARKET IN DRUG DISCOVERY
• PLANT BIOTECHNOLOGY AS A POTENTIAL MARKET FOR UPS
• OVERVIEW
• UBIQUITIN AS A TOOL FOR TRANSGENIC PLANTS
  • TABLE 54 U.S. MARKET FOR COTTON AND CORN, 2009 ($ BILLIONS)
• Ubiquitin as...(Continued)

Chapter-7: SCIENTIFIC/TECHNOLOGICAL BREAKTHROUGHS IN UPS

• OVERVIEW
  • TABLE 55 SCIENTIFIC AND TECHNOLOGICAL BREAKTHROUGHS IN UPS, 1977-2010
• PROTEASOME DISCOVERY AS A SCIENTIFIC BREAKTHROUGH
• NEW DEVELOPMENTS IN UPS DRUG DISCOVERY
• SIGNIFICANCE OF PATENTS
• OVERVIEW
• PATENT APPLICATIONS IN THE UPS RESEARCH FIELD IN 2009 VS. 2006 AS A REFLECTION OF RESEARCH TRENDS
  • TABLE 56 PATENT APPLICATIONS IN UBIQUTIN/PROTEASOME RESEARCH FILED BY PHARMACEUTICAL COMPANIES, 2009
  • TABLE 57 PATENT APPLICATIONS FILED BY PHARMACEUTICAL COMPANIES, 2006
• TENDENCIES OF PATENT APPLICATIONS OF UPS COMPANIES IN 1995-2005 VS. 2005-2010 AS A REFLECTION OF RESEARCH TRENDS
  • TABLE 58 PATENT APPLICATIONS IN UBIQUITN/PROTEASOME RESEARCH FILED BY LEADING PHARMACEUTICAL COMPANIES, 1995-2010 (NUMBER)
  • FIGURE 9 PATENT APPLICATIONS FILED BY PHARMACEUTICAL COMPANIES, 1995-2010 (NUMBER)
• PATENT APPLICATIONS BY REGION
  • TABLE 59 PATENT APPLICATIONS FILED IN THE UPS RESEARCH FIELD IN THE U.S. VS. EUROPE VS. JAPAN, 2009 (%)
  • FIGURE 10 PATENT APPLICATIONS FILED IN THE UPS RESEARCH FIELD IN THE U.S. VS. EUROPE VS. JAPAN, 2009 (%)
• ASSAY DEVELOPMENT AND REAGENTS FOR UPS DRUG DISCOVERY
• OVERVIEW
• CURRENT MARKET PARTICIPANTS
  • TABLE 60 COMPANIES INVOLVED IN THE PRODUCTION OF RESEARCH TOOLS FOR UPS, 2008 (UNIT/$ MILLIONS)
• Boston Biochem
• Enzo Life Sciences
• Life Technologies (Invitrogen)
• LifeSensors
• Meso Scale Discovery
• Proteasomes.com
• VLI Research
• ADDITIONAL MARKET PARTICIPANTS
• Sigma-Aldrich
• R&D Systems
• Millipore
• Genway
• BPS Bioscience
  • TABLE 61 COMPANIES INVOLVED IN THE PRODUCTION OF RESEARCH TOOLS FOR UPS AND THE PERCENTAGE OF UPS REAGENT TOOLS IN COMPANY CATALOGS (%)
• COMPETITIVE MARKET ANALYSIS
  • TABLE 62 SAMPLES OF PUBLISHED PRICES OF UPS REAGENTS FROM MAJOR SUPPLIERS OF UPS REAGENT TOOLS ($)
  • FIGURE 11 SAMPLES OF PUBLISHED PRICES OF UPS REAGENTS FROM MAJOR SUPPLIERS OF UPS REAGENT TOOLS ($)
• ASSAY DEVELOPMENT FOR UPS DRUG DISCOVERY
• OVERVIEW
  • TABLE 63 PROVIDERS OF SCREENING ASSAY TOOLS
• CURRENT MARKET PARTICIPANTS
• LanthaScreen Technology for Ubiquitination/Deconjugation Assays
• AlphaScreen Approach for Ubiquitination/Deconjugation Assays
• Cisbio
• Meso Scale Discovery
• LifeSensors
• Promega
• Miltenyi Biotec
• BioGenova
• Ubiquigent
• COMPETITIVE ANALYSIS
• UBIQUITIN AS A RESEARCH TOOL FOR OTHER DRUG DISCOVERY OPPORTUNITIES
• OVERVIEW
  • TABLE 64 COMPANIES SELLING UBIQUITIN AND UBLS AS REAGENT TOOLS FOR OTHER DRUG DISCOVERY APPLICATIONS
• CURRENT MARKET PARTICIPANTS
• Scil Proteins
• Dualsystems Biotech
• Split Ubiquitin System
• LifeSensors
• Life Technologies
• BIOINFORMATICS AS A TOOL IN UPS DRUG DISCOVERY
• OVERVIEW AND CURRENT MARKET PARTICIPANTS
• BioGenova
• Cognia Corp.
• Miltenyi Biotec

Chapter-8: MARKET SUMMARY

• TABLE 65 U.S. AND WORLDWIDE MARKETS FOR VELCADE, 2007 - 2009 ($ MILLIONS)
• FIGURE 12 U.S. AND WORLDWIDE MARKETS FOR VELCADE, 2007 - 2009 ($ MILLIONS)
• TABLE 66 COMPANIES WITH CURRENT OR PREVIOUS DEVELOPMENT OF A PROTEASOME INHIBITOR AS A THERAPEUTIC TREATMENT
• TABLE 67 CURRENT SPECIFIC TARGETS OF UPS IN DRUG DEVELOPMENT COMPANIES
• TABLE 67 (CONTINUED)
• TABLE 68 DRUG DISCOVERY IN COMPANIES WITH UPS RESEARCH BY MARKETS
• TABLE 68 (CONTINUED)
• TABLE 69 REAGENTS AND ASSAY DEVELOPMENT COMPANIES FOR UPS DRUG DISCOVERY

Chapter-9: SELECT COMPANY OVERVIEW

• AMGEN, INC.
• CEPHALON, INC.
• ELAN PHARMACEUTICALS
• ELAN PHARMACEUTICALS (CONTINUED)
• GENENTECH (HOFFMANN-LA ROCHE AG)
• F. HOFFMANN-LA ROCHE, LTD.
• JOHNSON & JOHNSON
• MILLENNIUM: THE TAKEDA ONCOLOGY COMPANY
• NEREUS PHARMACEUTICALS
• ONYX PHARMACEUTICALS, INC. (PROTEOLIX)
• PROGENRA
• PROTEOLOGICS, LTD.
• PROTEOLOGICS, LTD. (U.S.)
• RIGEL PHARMACEUTICALS, INC.
• RIGEL PHARMACEUTICALS, INC. (CONTINUED)

Chapter-10: DIRECTORY OF COMPANIES

• DIRECTORY OF COMPANIES
• DIRECTORY OF COMPANIES (CONTINUED)
• DIRECTORY OF COMPANIES (CONTINUED)
• DIRECTORY OF COMPANIES (CONTINUED)
• DIRECTORY OF COMPANIES (CONTINUED)
• DIRECTORY OF COMPANIES (CONTINUED)

Press Release

GLOBAL MARKETS FOR UBIQUITIN PROTEASOME DRUGS TO BE WORTH $3 BILLION IN 2015

Related Reports